Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free HSAQ Stock Alerts

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

Health Sciences Acquisitions Co. 2 logo
$4.46 +0.22 (+5.19%)
As of 08/10/2026
Compare

HSAQ vs. KRMD, INGN, APYX, STIM, and OWLT

Should you buy Health Sciences Acquisitions Co. 2 stock or one of its competitors? Health Sciences Acquisitions Co. 2's main competitors and comparable companies include KORU Medical Systems (KRMD), Inogen (INGN), Apyx Medical (APYX), Neuronetics (STIM), and Owlet (OWLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Health Sciences Acquisitions Co. 2 compare to KORU Medical Systems?

KORU Medical Systems (NASDAQ:KRMD) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 18.5% of KORU Medical Systems shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, KORU Medical Systems had 8 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 8 mentions for KORU Medical Systems and 0 mentions for Health Sciences Acquisitions Co. 2. KORU Medical Systems' average media sentiment score of 0.66 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that KORU Medical Systems is being referred to more favorably in the media.

Company Overall Sentiment
KORU Medical Systems Positive
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to KORU Medical Systems' net margin of -4.03%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat KORU Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
KORU Medical Systems-4.03% -10.63% -6.51%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than KORU Medical Systems.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KORU Medical Systems$45.11M3.51-$2.64M-$0.04N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

KORU Medical Systems has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

KORU Medical Systems presently has a consensus target price of $7.00, suggesting a potential upside of 102.90%. Given KORU Medical Systems' stronger consensus rating and higher possible upside, research analysts plainly believe KORU Medical Systems is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KORU Medical Systems
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

KORU Medical Systems beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Inogen?

Inogen (NASDAQ:INGN) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Inogen had 10 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 10 mentions for Inogen and 0 mentions for Health Sciences Acquisitions Co. 2. Inogen's average media sentiment score of 0.27 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Inogen is being referred to more favorably in the media.

Company Overall Sentiment
Inogen Neutral
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Inogen's net margin of -6.94%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Inogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Inogen-6.94% -13.17% -8.36%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Inogen has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Inogen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inogen$348.67M0.45-$22.75M-$0.90N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

89.9% of Inogen shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 2.5% of Inogen shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inogen
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Inogen beats Health Sciences Acquisitions Co. 2 on 7 of the 12 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Apyx Medical?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Apyx Medical (NASDAQ:APYX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 55.3% of Apyx Medical shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Comparatively, 15.9% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Apyx Medical had 23 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 23 mentions for Apyx Medical and 0 mentions for Health Sciences Acquisitions Co. 2. Apyx Medical's average media sentiment score of 0.10 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Health Sciences Acquisitions Co. 2 Neutral
Apyx Medical Neutral

Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Apyx Medical has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Apyx Medical has a consensus price target of $6.60, indicating a potential upside of 118.54%. Given Apyx Medical's stronger consensus rating and higher probable upside, analysts clearly believe Apyx Medical is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Apyx Medical
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Apyx Medical's net margin of -14.78%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Apyx Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Health Sciences Acquisitions Co. 2N/A N/A -2.38%
Apyx Medical -14.78%-76.60%-13.91%

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Apyx Medical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A
Apyx Medical$52.84M2.41-$11.21M-$0.20N/A

Summary

Apyx Medical beats Health Sciences Acquisitions Co. 2 on 8 of the 14 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Neuronetics had 13 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 13 mentions for Neuronetics and 0 mentions for Health Sciences Acquisitions Co. 2. Neuronetics' average media sentiment score of 0.65 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Neuronetics is being referred to more favorably in the media.

Company Overall Sentiment
Neuronetics Positive
Health Sciences Acquisitions Co. 2 Neutral

Neuronetics currently has a consensus price target of $4.50, suggesting a potential upside of 41.07%. Given Neuronetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Neuronetics is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuronetics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Neuronetics' net margin of -24.48%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Neuronetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuronetics-24.48% -139.83% -27.13%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Neuronetics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Neuronetics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuronetics$151.64M1.46-$39M-$0.54N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Neuronetics beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Owlet?

Owlet (NYSE:OWLT) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Owlet has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Owlet's net margin of -42.54%.

Company Net Margins Return on Equity Return on Assets
Owlet-42.54% N/A -18.02%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

72.6% of Owlet shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 36.2% of Owlet shares are owned by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Owlet.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Owlet$105.70M1.50-$39.68M-$3.07N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Owlet presently has a consensus target price of $15.00, indicating a potential upside of 174.78%. Given Owlet's stronger consensus rating and higher probable upside, analysts plainly believe Owlet is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Owlet
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Owlet had 6 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 6 mentions for Owlet and 0 mentions for Health Sciences Acquisitions Co. 2. Owlet's average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company Overall Sentiment
Owlet Neutral
Health Sciences Acquisitions Co. 2 Neutral

Summary

Owlet beats Health Sciences Acquisitions Co. 2 on 7 of the 11 factors compared between the two stocks.

Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically

Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HSAQ vs. The Competition

Export
MetricHealth Sciences Acquisitions Co. 2Healthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$50.01M$5.85B$7.08B$12.96B
Dividend YieldN/A1.76%2.57%10.34%
P/E RatioN/A25.09268.4325.05
Price / SalesN/A63.06596.5689.39
Price / CashN/A33.3872.2650.42
Price / Book-7.195.8913.216.18
Net Income-$380K$147.25M$3.44B$347.05M
7 Day Performance4.45%2.73%2.10%1.25%
1 Month Performance11.78%2.47%-0.23%-0.64%
1 Year Performance64.58%9.44%70.30%20.12%

Health Sciences Acquisitions Co. 2 Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HSAQ
Health Sciences Acquisitions Co. 2
N/A$4.46
+5.2%		N/A+64.6%$50.01MN/AN/A4
KRMD
KORU Medical Systems
4.0487 of 5 stars		$4.13
-2.6%		$7.25
+75.5%		-14.6%$189.69M$41.13MN/A80
INGN
Inogen
1.3855 of 5 stars		$6.56
-5.2%		N/A-16.2%$177.65M$348.67MN/A1,030
APYX
Apyx Medical
2.4541 of 5 stars		$4.14
-3.3%		$6.60
+59.4%		+35.4%$173.51M$52.84MN/A270
STIM
Neuronetics
4.166 of 5 stars		$2.35
+2.2%		$4.00
+70.2%		-18.6%$163.54M$149.16MN/A180

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HSAQ) was last updated on 8/12/2026 by MarketBeat.com Staff.
From Our Partners
This Junior Silver Explorer Is Closing In on Its Biggest Catalyst
A past-producing Nevada silver project holds a historical 36 million ounce silver-equivalent resource, plus mo...
Wall Street Logic | Sponsoredtc pixel
7 Bankers Met in Secret (Now We Pay for It)
A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...
Decentralized Masters | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel